September 21, 2011
Wellesley, Mass. – In a recent release, GENERIC DRUGS: THE GLOBAL MARKET (PHM009F) from BCC Research (www.bccresearch.com), the total global market for generic drugs is estimated to be worth $225 billion in 2011, and is expected to increase at a compound annual growth rate (CAGR) of 9.7% during the next five years. At this rate, the overall market value will reach $358 billion in 2016.
The global generic drug market can be broken down into five regions – North America, emerging markets, major Europe, Japan, and the rest of the world.
The North American region, which is composed of the United States and Canada, held a value of $73 billion in 2011, and is expected to increase at a CAGR of 7.9% to reach $107 billion in 2016.
The emerging markets region, made up of Brazil, China, India, Mexico, and Russia, held a value of $57 billion in 2011, and is expected to increase at a CAGR of 15.1% to reach $115 billion in 2016.
The major European region, comprised of France, Germany, Italy, Spain, and the U.K., was worth $42 billion in 2011 and should be worth $63 billion in 2016, a CAGR of 8.4%.
The Japanese region, worth $9 billion in 2011, should be worth $15 billion in 2016, a CAGR of 12.1%.
The region composed of the rest of the world was valued at $44 billion in 2011 and, after increasing at a CAGR of 5.7%, should be worth $58 billion in 2016.
This is a time of growth and change for the generic pharmaceuticals sector. Major aspects that combine to create an opportunity for an up-to-date market analysis include an increase in the demand for generics because of pressure to control healthcare costs, several blockbuster pharmaceutical brands are coming off-patent and are therefore open to generic competition, and the international landscape is changing for generics as for all pharmaceuticals.
The aim of this report is to provide detailed market, technology, and industry analyses to help readers quantify and qualify the market for prescription generic drugs. Important trends are identified and sales forecasts by product categories and major country markets are provided through 2016. The report examines strategies employed by companies specializing in generics to meet the challenges of this highly competitive market, while also summarizing strategies employed by “originator” companies to forestall generic competition.
This report is designed to satisfy the information needs of a wide variety of individuals involved in the generics marketplace, including company senior management executives, managers and executives in marketing, research, planning, and also sales departments who need readable, comprehensive, and up-to-date background on the marketplace in which they are operating.
In addition to PHM009F, BCC has released PHM106A, PHM107A, and PHM108A, three reports that respectively cover the American, European, and Asian generic drug markets in further detail.
Generic Drugs: The Global Market( PHM009F )
Publish Date: Sep 2011
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email press@bccresearch.com or visit www.bccresearch.com/media to request access to our library of market research.